Physician profile
Ted Warren
NPI 1306878509
$7,994.93
in general payments reported to CMS, 2019-2025
34 companies · $1,107 in 2025
The $1,107 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,194 · 2020: $605 · 2021: $726 · 2022: $987 · 2023: $1,192 · 2024: $1,184 · 2025: $1,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,483.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,467.83 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,107.50 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $869.09 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $670.08 | 2019-2025 | |
| Allergan, INC. | $509.36 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $485.71 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $373.41 | 2019-2023 | Evenity, Prolia |
| Lilly USA, LLC | $365.61 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $330.52 | 2019-2023 | Belsomra, Steglatro, Januvia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.09 | 2019-2025 | Synjardy, Jardiance |
| Janssen Pharmaceuticals, INC | $173.79 | 2019-2022 | |
| Astellas Pharma US INC | $173.26 | 2019-2025 | Veozah |
| Abbott Laboratories | $124.91 | 2023-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $124.85 | 2019-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $112.33 | 2022-2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $110.47 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $74.85 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $73.37 | 2021 | |
| Sanofi-Aventis U.S. LLC | $68.95 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $67.75 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.50 | 2019-2023 | Xifaxan |
| Amarin Pharma, INC. | $59.40 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $48.38 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $47.04 | 2024-2025 | Gemtesa |
| Boston Scientific Corporation | $40.79 | 2019 | |
| Dexcom, INC. | $40.04 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $34.81 | 2024 | Cologuard Collection Kit |
| Organon LLC | $29.67 | 2025 | Vtama |
| Corcept Therapeutics | $28.24 | 2025 | Korlym |
| Axsome Therapeutics, INC. | $20.00 | 2025 | Auvelity |
| Lundbeck LLC | $18.80 | 2025 | Rexulti |
| Shield Therapeutics INC | $15.52 | 2025 | |
| Axonics, INC. | $14.28 | 2022 | |
| Genentech USA, INC. | $13.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ted Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.